Quarterly report pursuant to Section 13 or 15(d)

Note 3 - Discontinued Operations (Tables)

v3.7.0.1
Note 3 - Discontinued Operations (Tables)
 6 Months Ended
Jun. 30, 2017
Notes Tables  
Disposal Groups, Including Discontinued Operations [Table Text Block]
 
 
June 30
,
2017
 
 
December 31,
2016
 
Accounts and other receivables
   $
—
     $
1,598,994
  
Inventory, net
    
—
      
1,374,618
  
Prepaid expenses
    
—
      
170,635
  
Assets associated with discontinued operations, current
    
—
      
3,144,247
  
Property and equipment, net of accumulated depreciation
    
—
      
70,973
  
Patents and trademarks, net of accumulated amortization
    
—
      
34,282
  
Assets associated with discontinued operations, noncurrent
    
—
      
105,255
  
Total assets associated with discontinued operations
   $
—
     $
3,249,502
  
                 
Accounts payable
   $
21,255
     $
1,957,938
  
Accrued liabilities
    
33,804
      
607,659
  
Deferred revenue
    
—
      
2,300,000
  
Liabilities associated with discontinued operations, current
   $
55,059
     $
4,865,597
  
 
 
Three Months Ended
June 30,
 
 
Six Months Ended
June 30,
 
 
 
2017
 
 
2016
 
 
2017
 
 
2016
 
Revenue:
                                
Lymphoseek sales revenue
   $
9,663
     $
4,227,320
     $
2,926,876
     $
8,001,200
  
Grant and other revenue
    
—
      
—
      
—
      
190
  
Total revenue
    
9,663
      
4,227,320
      
2,926,876
      
8,001,390
  
Cost of goods sold
    
24,216
      
559,933
      
388,408
      
1,093,373
  
Gross profit
    
(14,553
)
    
3,667,387
      
2,538,468
      
6,908,017
  
Operating expenses:
                                
Research and development
    
75,196
      
506,370
      
358,729
      
1,093,619
  
Selling, general and administrative
    
—
 
    
1,500,324
      
820,203
      
2,963,858
  
Total operating expenses
    
75,196
      
2,006,694
      
1,178,932
      
4,057,477
  
Income (loss) from discontinued operations
    
(89,749
)
    
1,660,693
      
1,359,536
      
2,850,540
  
Interest expense
    
—
      
(7,525,483
)
    
(1,718,506
)
    
(9,719,763
)
Loss before income taxes
    
(89,749
)
    
(5,864,790
)
    
(358,970
)
    
(6,869,223
)
Benefit from income taxes
    
7,373
      
—
      
20,733
      
—
  
Loss from discontinued operations
   $
(82,376
)
   $
(5,864,790
)
   $
(338,237
)
   $
(6,869,223
)